Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

Subscribe to our newsletter and never miss a post!

* indicates required

Medicines Law & Policy will use the information you provide to keep you up-to-date when we post new research and insight. You can change your mind about receiving our newsletter any time by clicking the unsubscribe link in the footer of any email you receive from us. We will treat your information with respect. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

We value your privacy

We use cookies to enhance your browsing experience, serve personalised content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Menu
Contact Us
Subscribe
Menu

Blog

The latest thoughts from Medicines Law & Policy partners.

Latest

A better way to solve a crisis: A new mechanism for incentivising R&D on...

Kaitlin Mara -
Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...

The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...

Ellen 't Hoen -
Thank you for the opportunity to make a brief statement. The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...

Trump Administration poses an unprecedented threat to life-saving health programmes 

Ellen 't Hoen and Kaitlin Mara -
On his first day in office, US President Trump issued several executive orders, one of which concerns US foreign aid. This order included a...

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Medicines Law & Policy -
Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

UN “Pact for the Future” intellectual property actions need revision to ensure innovation and...

Ellen 't Hoen -
UPDATE: From 22-23 September 2024, the Summit of the Future took place and adopted the Pact for the Future. The intellectual property paragraph of...

World Trade Organization Members Embark on Review of the TRIPS Agreement

Ellen 't Hoen -
The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review...

MSF’s Access Campaign is an invaluable actor in global health; shutting it down is...

Medicines Law & Policy -
On 20 June, STAT News reported that Médecins Sans Frontières (MSF) is closing down their Access Campaign, effective as of 31 December 2024. It...

The new IP strategy of war-torn Ukraine should prioritise public health and national security

Olga Gurgula -
Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...

Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case

Kaitlin Mara -
“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...

Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect...

Ellen 't Hoen -
The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...
123...11Page 1 of 11

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Never miss a post! Sign up for ML&P's newsletter.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.